ACROBiosystems社 【Inspiring Target】CXCR4 and CCR5, Promising Targets for HIV and Tumor Therapy
【Inspiring Target】CXCR4 and CCR5, Promising Targets for HIV and Tumor Therapy
Even though HIV is a multifactorial disease, studies have shown that specific targeting of CXCR4 and CCR5 is a promising therapeutic strategy for HIV as well as other immune conditions such as tumors.
ACROBiosystems is focused on overcoming the challenges during the preparation of GPCRs. We provide full-length GPCRs proteins via "FLAG" technology platforms to assist our customers and collaborators with antibody drugs and therapeutic strategies. Recently, full-length CCR5 and CXCR4 proteins have been developed and launched, do not hesitate to consult and order.
Product Features
Full-length CCR5-VLP Protein (Cat. No. CC5-H52P3)
>> High bioactivity
Immobilized Human CCR5 Full-Length Protein-VLP (Cat. No. CC5-H52P3) at 2 μg/mL (100 μL/well) can bind Anti-Human CCR5 Antibody, Mouse IgG2a with a linear range of 2-78 ng/mL (QC tested).
>> High identity
The mean peak Radius of VLP is 130-170 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Full-length CXCR4 Protein-VLP Protein (Cat. No. CX4-H5219)
>> High bioactivity
Immobilized Human CXCR4 Full-Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).
>> High identity
The mean peak Radius of VLP is 110-170 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
>> Learn more about FLAG: multi-pass transmembrane proteins and technology platforms
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。